Could a Smartwatch-Like device ease scleroderma symptoms?

NCT ID NCT06675344

Recruiting now Symptom relief Sponsor: Robyn T. Domsic, MD, MPH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a wearable device called Apollo Neuro can reduce fatigue and Raynaud's attacks in people with systemic sclerosis (scleroderma). The device delivers gentle vibrations to the skin. 160 participants will wear it daily for 6 weeks and report their symptoms. The goal is to improve quality of life without medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Apollo Neuro wearable device (transcutaneous vibratory stimulation)
What this could lead to: If it works, this could offer a drug-free way to manage fatigue and Raynaud attacks in people with scleroderma.
What could go wrong: This is a small, early-stage trial testing a device, not a cure. The benefits may be modest or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse scleroderma Fatigue Raynaud disease systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

DelRicht Research Center
RECRUITING

New Orleans, Louisiana, 70115, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Pittsburgh and UPMC Scleroderma Center
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.